IgG Antibodies to Cyclic Citrullinated Peptides Exhibit Profiles Specific in Terms of IgG Subclasses, Fc-Glycans and a Fab-Peptide Sequence
Fragment crystallizable region
Subclass
Immunoglobulin Fc Fragments
Glycoproteomics
DOI:
10.1371/journal.pone.0113924
Publication Date:
2014-11-26T22:54:36Z
AUTHORS (11)
ABSTRACT
The Fc-glycan profile of IgG1 anti-citrullinated peptide antibodies (ACPA) in rheumatoid arthritis (RA) patients has recently been reported to be different from non-ACPA IgG1, a phenomenon which likely plays role RA pathogenesis. Herein we investigate the Fc-glycosylation pattern all ACPA-IgG isotypes and simultaneously detail IgG protein-chain sequence repertoire. serum or plasma (S/P, n = 14) synovial fluid (SF, 4) 18 ACPA-positive RA-patients was enriched using Protein G columns followed by ACPA-purification on cyclic citrullinated peptide-2 (CCP2)-coupled columns. Paired ACPA (anti-CCP2 eluted IgG) flow through (FT) fractions were analyzed LC-MS/MS-proteomics. peptides, corresponding Fc-glycopeptides quantified interrogated uni- multivariate statistics. Fc-glycans IgG4 EEQFNSTYR validated protein A column purification. Relative FT-IgG4, ACPA-IgG4 Fc-glycan-profile contained lower amounts (p 0.002) agalacto asialylated core-fucosylated biantennary form (FA2) higher content 0.001) sialylated glycans. Novel differences ACPA-IgG1 compared FT-IgG1 observed distribution bisected forms (n 5, p 0.0001, decrease) mono-antennnary 3, 0.02, increase). Our study also confirmed abundance FA2 afucosylated 4, relative as well IgG2 0.0000001) elevated 0.004) FT. One λ-variable significantly increased 0.0001). In conclusion, both are distinct. Given that have Fc-receptor complement binding affinities, this affects effector- immune-regulatory functions an isotype-specific manner. These findings further highlight importance antibody characterization relation functional vivo vitro studies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (37)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....